- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Clinical, P3 data, Journal: Summary of Research: Ensifentrine, a Novel Phosphodiesterase (Pubmed Central) - Mar 25, 2026
It also reduced the rate and risk of flare-ups (called exacerbations) and was well tolerated. These results support the use of ensifentrine as an effective and well-tolerated treatment for people with COPD.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Mechanism of Ensifentrine Protection Against Endothelial Injury in COPD-associated Pulmonary Hypertension (W230 (Level II, OCCC West Concourse); Poster Board # 411) - Mar 3, 2026 - Abstract #ATS2026ATS_8434;
Suppression of cAMP-PKA/EPAC signaling may play a key role in endothelial dysfunction in COPD-PH. Restoration of this pathway via PDE3/4 inhibition may protect against CS-induced endothelial injury, supporting cAMP-PKA/EPAC signaling as a potential novel therapeutic target for COPD-PH.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Modulating Inflammation in the Target Tissue: Anti-Inflammatory Effects of Ensifentrine in Medium Bronchi and Small Airways of COPD Donors (W230 (Level II, OCCC West Concourse); Poster Board # 405) - Mar 3, 2026 - Abstract #ATS2026ATS_8428;
Methods Human medium bronchial rings, small airways, and primary bronchial epithelial cells from COPD lobectomy donors were treated with concentration-response curves (10nM-1mM) of ensifentrine or roflumilast (a PDE4 inhibitor used as reference), with epithelium?intact and epithelium?denuded preparations where specified...Ensifentrine was combined at these isoeffective concentrations with formoterol, glycopyrronium, formoterol+glycopyrronium, formoterol+beclometasone, and formoterol+glycopyrronium+beclometasone...These findings support further clinical evaluation of optimized combinations that leverage synergistic interactions to enhance therapeutic efficacy in COPD management. This study was funded by Verona Pharma plc.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Health Care Resource Utilization and Exacerbations in Patients Starting Ensifentrine: A Real-World Claims Analysis (W230 (Level II, OCCC West Concourse); Poster Board # 422) - Mar 3, 2026 - Abstract #ATS2026ATS_3030;
CONCLUSION : In a population of patients with COPD taking dual/triple maintenance therapy, the addition of ensifentrine reduced resource-intensive severe exacerbation events and care, while increasing outpatient care suggesting a lessening of exacerbation severity. These real-world outcomes support the use of ensifentrine as an effective treatment for patients with COPD who need additional options to prevent severe outcomes.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Comparative Effectiveness of Ensifentrine vs Roflumilast on Clinical Outcomes in Chronic Obstructive Pulmonary Disease (W230 (Level II, OCCC West Concourse); Poster Board # 418) - Mar 3, 2026 - Abstract #ATS2026ATS_3026;
Ensifentrine demonstrated lower rates of COPD exacerbations, hospitalization, pneumonia, and other secondary outcomes compared to roflumilast. This is the first study directly evaluating outcomes between ensifentrine and roflumilast, supporting the need for future prospective studies to help guide clinicians on decision making around the numerous COPD adjunctive treatment options.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Goal Directed Therapy in COPD: Realization of the Gold and Chest Standard (Area H, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P1604) - Mar 3, 2026 - Abstract #ATS2026ATS_1453;
Our cohort includes GOLD-E, and should all be on LAMA and LABA. Noted greater prescription of LAMA in HiDys.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Review, Journal: Advancing COPD management through novel pharmacological agents: ensifentrine and dupilumab. (Pubmed Central) - Dec 18, 2025
By focusing on disease endotypes, these novel therapies underscore the growing role of personalised treatment approaches in COPD. Continued investigation into biomarkers and long-term outcomes will be essential for integrating these therapies into routine clinical practice.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Journal: Ensifentrine: A Potential Shift in COPD Management. (Pubmed Central) - Dec 11, 2025
Continued investigation into biomarkers and long-term outcomes will be essential for integrating these therapies into routine clinical practice. No abstract available
- |||||||||| Journal: Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast. (Pubmed Central) - Nov 21, 2025
The anti-inflammatory effects of ensifentrine were lower compared to the PDE4 inhibitors tested. In the phase 3, 52-week ASPEN trial, brensocatib significantly reduced exacerbation burden, and the 25-mg dose reduced lung function decline and nominally significantly
- |||||||||| Review, Journal: Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder. (Pubmed Central) - Nov 5, 2025
Pharmacists can assist in medication optimization and access; however, patient-specific factors like exacerbation history, blood eosinophils, and COPD endotype must be considered. Implementing early identification screening tools such as CAPTURE should factor into patient assessment.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Journal: Pharmacological management of COPD. (Pubmed Central) - Nov 1, 2025
The positive clinical trial results for dupilumab (a monoclonal antibody directed against the shared IL-4 and IL-13 receptor) and ensifentrine (an inhibitor of phosphodiesterase 3 and 4) represent significant advances in the pharmacological management of COPD. This review describes the recent progress in COPD pharmacology, covering novel molecules, new evidence and changes in clinical practice.
- |||||||||| ensifentrine/glycopyrrolate (MK5884A) / Merck (MSD), Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Enrollment closed: A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Oct 28, 2025
P2, N=33, Active, not recruiting,
This review describes the recent progress in COPD pharmacology, covering novel molecules, new evidence and changes in clinical practice. Recruiting --> Active, not recruiting
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Review, Journal: Anti-Inflammatory Agents for the Management of COPD - Quo Vadis? (Pubmed Central) - Oct 26, 2025
Among these, inhaled phosphodiesterase 4 (PDE4) inhibitors and especially dual PDE3/4 inhibitors like ensifentrine have demonstrated promising anti-inflammatory and bronchodilator effects, with ensifentrine recently being added in our arsenal of treatment options...Dupilumab, a mAb targeting IL-4/13, is the first biologic officially approved for COPD...While some novel compounds have failed to demonstrate clinical benefit or were discontinued due to futility, the constantly evolving therapeutic landscape highlights the importance of a personalized approach, based on inflammatory phenotypes. Ongoing and future trials could elucidate the role of these innovative agents in improving outcomes for COPD patients and may reshape standard management paradigms.
- |||||||||| ensifentrine/glycopyrrolate (MK5884A) / Merck (MSD), Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Enrollment open: A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Oct 3, 2025
P2, N=30, Recruiting,
Notably, this study highlights the potential for improving PDE3A selectivity and designing more effective and selective inhibitors for COPD and other respiratory conditions. Not yet recruiting --> Recruiting
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Verona Pharma
Journal: Anti-Inflammatory Activity of Ensifentrine, a Novel, Selective Dual Inhibitor of Phosphodiesterase (PDE)3 and PDE4. (Pubmed Central) - Sep 26, 2025
This manuscript describes further evidence that ensifentrine is a selective dual inhibitor of both human PDE3 and PDE4 enzymes and that this drug has significant anti-inflammatory activity in vivo in both allergic guinea pigs and non-human primates. This dual bronchodilator and anti-inflammatory activity of ensifentrine makes it a promising strategy as a novel inhaled "bifunctional" drug for the treatment of obstructive and inflammatory diseases of the respiratory tract.
- |||||||||| ensifentrine/glycopyrrolate (MK-5884A) / Merck (MSD), Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Enrollment status, Monotherapy: A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD (clinicaltrials.gov) - Sep 13, 2025
P2, N=480, Recruiting,
This dual bronchodilator and anti-inflammatory activity of ensifentrine makes it a promising strategy as a novel inhaled "bifunctional" drug for the treatment of obstructive and inflammatory diseases of the respiratory tract. Enrolling by invitation --> Recruiting
- |||||||||| 7827: Beyond the Sputum: Novel Strategies in Bronchiectasis Management (McCormick Place - Lakeside Center Exhibit Hall Experience CHEST) - Sep 10, 2025 - Abstract #CHEST2025CHEST_7048;
Description This session will present emerging and novel strategies in the diagnosis, phenotyping, and treatment of bronchiectasis while engaging the audience in critical thinking about how to integrate them into practice. Topics covered include targeted anti- inflammatory therapy, microbiome therapy, novel airway clearance strategies, and the use of artificial intelligence and digital health tools.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
7818: Bridging Clinical Evidence and Practice: The Role of Ensifentrine in COPD Treatment (McCormick Place - Lakeside Center Exhibit Hall Experience CHEST) - Sep 10, 2025 - Abstract #CHEST2025CHEST_6957;
Additionally, this session will evaluate strategies to integrate ensifentrine and explore barriers to implementation while synthesizing clinical evidence with experiential insights from outpatient care settings. Through this comprehensive approach, the session aims to foster critical thinking and collaborative dialogue on how to optimize therapeutic outcomes using ensifentrine, ultimately improving patient-centered care in COPD management.
- |||||||||| ensifentrine/glycopyrrolate (MK-5884A) / Merck (MSD), Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
Enrollment open, Monotherapy: A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD (clinicaltrials.gov) - Sep 5, 2025
P2, N=480, Enrolling by invitation,
Through this comprehensive approach, the session aims to foster critical thinking and collaborative dialogue on how to optimize therapeutic outcomes using ensifentrine, ultimately improving patient-centered care in COPD management. Not yet recruiting --> Enrolling by invitation
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Ohtuvayre (ensifentrine nebulized) / Merck (MSD), Daliresp (roflumilast) / AstraZeneca
1118: COPD Management: Advanced Pharmacological Options (McCormick Place - Lakeside Center 352) - Jun 30, 2025 - Abstract #CHEST2025CHEST_5133;
Review the evidence for ensifentrine, roflumilast, and azithromycin and provide a framework for drug selection 3. Learn about the currently available and emerging biologic therapeutics in the management of COPD
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
ENSIFENTRINE IMPROVED LUNG FUNCTION, SYMPTOMS, AND QUALITY OF LIFE REGARDLESS OF EXACERBATION HISTORY (McCormick Place - Lakeside Center Exhibit Hall Poster Area 3) - Jun 30, 2025 - Abstract #CHEST2025CHEST_4904;
Ensifentrine also provided early and sustained improvements in symptoms, dyspnea, and quality of life regardless of baseline exacerbation history. CLINICAL IMPLICATIONS: Ensifentrine provides a novel mechanism of action with dual bronchodilator and anti- inflammatory effects which improves lung function and symptom control in COPD patients with and without recent history of COPD exacerbations.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
ENSIFENTRINE IMPROVED LUNG FUNCTION, SYMPTOMS, QUALITY OF LIFE, AND EXACERBATION RATE AND RISK REGARDLESS OF SEX (McCormick Place - Lakeside Center Exhibit Hall Poster Area 3) - Jun 30, 2025 - Abstract #CHEST2025CHEST_4903;
CLINICAL IMPLICATIONS: Sex-differences in COPD can affect disease mechanisms, airway structures, symptoms, and treatment responses. Ensifentrine, a novel agent with dual bronchodilator and anti-inflammatory action, provides clinical benefit including improvement in lung function, symptoms, and quality of life in a broad population of patients with moderate-to- severe COPD regardless of patient sex.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
EFFICACY OF ENSIFENTRINE IN PATIENTS WITH A HISTORY OF COPD EXACERBATIONS AND EOSINOPHILS LESS THAN 300 CELLS/ (McCormick Place - Lakeside Center Exhibit Hall Rapid Fire Area 3A) - Jun 30, 2025 - Abstract #CHEST2025CHEST_3814;
Although not statistically significant, the reduction in the rate and risk of moderate/severe exacerbations observed in this subgroup is consistent with the magnitude of effect observed in these parameters in the overall ENHANCE population. CLINICAL IMPLICATIONS: Ensifentrine provides a novel mechanism of action for clinically meaningful improvements in lung function, symptoms and quality of life, and reduction in exacerbations in patients with a recent exacerbation and eosinophils <300 cells/?L, who would not be appropriate candidates for biologic treatments.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Merck (MSD)
ENSIFENTRINE IMPROVED SLEEP IN PATIENTS WITH MODERATE-TO-SEVERE COPD IN THE PHASE 3 ENHANCE TRIALS (McCormick Place - Lakeside Center Exhibit Hall Rapid Fire Area 3A) - Jun 30, 2025 - Abstract #CHEST2025CHEST_3811;
CLINICAL IMPLICATIONS: Many patients with COPD are impacted by significant sleep disturbances from respiratory symptoms. Ensifentrine provides early and sustained improvements in sleep for these patients which may be from improvement in COPD symptoms.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Ohtuvayre (ensifentrine nebulized) / Merck (MSD), Daliresp (roflumilast) / AstraZeneca
APPROACH TO A GROWING LANDSCAPE OF PHARMACOLOGIC THERAPIES FOR COPD PATIENTS WITH HIGH EXACERBATION RISK (McCormick Place - Lakeside Center Exhibit Hall Rapid Fire Area 4A) - Jun 30, 2025 - Abstract #CHEST2025CHEST_2847;
With a growing landscape of pharmacologic options to help reduce the risk of COPD exacerbations, it is important for patients with high exacerbation risk be continually evaluated for additional therapies. Based on the data from this cohort, the majority of patients hospitalized due AECOPD would benefit from an additional pharmacologic agent with their optimized inhaled therapies.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Verona Pharma, Daliresp (roflumilast) / AstraZeneca
Review, Journal: Ensifentrine: A Novel Option for Maintenance of Chronic Obstructive Pulmonary Disease. (Pubmed Central) - Jun 27, 2025
Ensifentrine provides clinically meaningful improvements in symptoms, including dyspnea, and quality of life for patients with COPD, even in those who are not experiencing exacerbations. Data Sources: A literature search of studies took place between October 2024 and December 2024 on PubMed using the terms ensifentrine, roflumilast, Ohtuvayre
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Verona Pharma
Clinical, Retrospective data, Review, Journal: Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials. (Pubmed Central) - Jun 24, 2025
In conclusion, owing to its dual effects, ensifentrine has a significant impact on improving pulmonary function and quality of life with minimal side effects. Promising results are expected if implied by synergizing with other drugs, however, more studies are needed to study the long-term effect on disease progression.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Ohtuvayre (ensifentrine nebulized) / Verona Pharma
Review, Journal: Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments. (Pubmed Central) - Jun 24, 2025
The use of BEC as a biomarker to guide pharmacological treatment has enabled a precision medicine approach in COPD. This article reviews recent advances in the pharmacological treatment of COPD, encompassing the optimum use of inhaled combination treatments and the evidence to support the use of the novel inhaled phosphodiesterase inhibitor ensifentrine and monoclonal antibodies in patients with COPD.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Verona Pharma
The effect of ensifentrine on COPD symptoms and quality of life according to baseline dyspnea level (PS-15; Board Number: 19) - Jun 11, 2025 - Abstract #ERS2025ERS_4133;
These findings support the use of ensifentrine in a broad population of patients with moderate to severe COPD. Treatment with ensifentrine produced early, sustained, and clinically meaningful improvements in symptoms and quality of life in patients with moderate-to-severe COPD, regardless of baseline dyspnea level.
- |||||||||| Ohtuvayre (ensifentrine nebulized) / Verona Pharma
Ensifentrine induces anti-inflammatory effects in isolated airways from COPD donors (PS-15; Board Number: 18) - Jun 11, 2025 - Abstract #ERS2025ERS_4132;
These findings support the potential of ensifentrine as an adjunctive therapy in COPD management and help explain its effectiveness in reducing the risk of exacerbation, as evidenced by the ENHANCE trials. Funding: Verona Pharma plc.
|
